KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

FDA Just Approved KarXT - Is This the Future of Schizophrenia Treatment?
📃Subscribe to Newsletter: www.thecarlatr...
🎧Full Podcast: podcasts.apple...
📖Medication Fact Book: www.thecarlatr...
================
Follow Carlat:
🔴SUBSCRIBE ► / @thecarlatreport
➡️Twitter: / CarlatPsych
================
In this video, we take an in-depth look at the recently FDA-approved antipsychotic, KarXT, also known by its brand name Cobenfy. This new drug represents a major breakthrough in schizophrenia treatment because, unlike traditional antipsychotics, it doesn’t rely on blocking dopamine receptors. Instead, KarXT works through a muscarinic agonist mechanism, making it a completely different approach to managing schizophrenia and other psychotic disorders.
We'll start by explaining the science behind KarXT and how its combination of Xanomeline and Trospium works together to provide effective symptom control while reducing many of the typical side effects seen in older medications. The benefits of KarXT go beyond just managing symptoms-its novel mechanism means patients may experience fewer issues like weight gain, fatigue, and extrapyramidal symptoms that are common with older antipsychotics. We’ll discuss what this Cobenfy approval means for patients and the potential impact it could have on psychiatric care moving forward.
We’ll also cover the side effects of KarXT, including both the cholinergic and anticholinergic effects that you might expect from this type of medication. While KarXT may offer fewer of the traditional side effects, it does come with its own considerations, such as dry mouth, constipation, and nausea. Plus, we’ll look into how Cobenfy compares to traditional dopamine-blocking antipsychotics and what clinicians should keep in mind when prescribing it.
This video also touches on why the KarXT efficacy trials have generated so much excitement in the psychiatric community. The EMERGENT trials, which tested KarXT for schizophrenia, showed promising results with fewer discontinuations due to side effects compared to placebo. We’ll explain what these results mean and why Cobenfy for schizophrenia treatment could be a major advancement in the field of psychopharmacology.
If you’re interested in the future of mental health treatment or if you’re a healthcare professional looking to stay updated on the latest developments, this video will give you a thorough overview of KarXT, its unique approach, and how it stands out from other antipsychotics on the market. We’ll also share our thoughts on what this Cobenfy approval means for patients and whether KarXT could be the future of antipsychotic medication.
By the end of this video, you’ll have a clear understanding of the benefits of KarXT, how it works, what to watch for in terms of KarXT side effects, and why this drug is considered a significant breakthrough in schizophrenia treatment.

[@mahsahamid3500]

Helpful and educational, as always!

[@thecarlatreport]

Thanks!

[@jicalzad]

reducing/eliminating risk of drug-induced movement disorders can be viewed as game changing

[@thecarlatreport]

True!

[@kahleentenshi]

Beautiful video!

[@thecarlatreport]

Thank you very much!

[@jpie78]

Great video! Easy to understand and informative.

[@TheCuriousPsych]

I shall always like your videos. It is exciting to have a newer mechanism of action in the market but I am hesitant to prescribe it until we have independent RTCs

[@thecarlatreport]

Appreciate it! We agree.

[@benclark-cu4ct]

Sounds like it could be a good tool, BID dosing with schizophrenics patients does sound daunting though

[@thecarlatreport]

BID pales to side-effects though!

[@venkatelumalai1207]

Cobenfy tablet When will come in India sir

[@sharmarustam]

Hello bro are you suffering from schizophrenia? I suffer from it.